Our R&D team partners with world-class physicians to develop innovative products that meet and exceed their clinical needs in each specialty. We rigorously test our products in cadaver labs that closely reflect the clinical environment to validate the design and procedure.
Our educational programs are focused on teaching new and innovative surgical techniques. We invest heavily in developing surgeons’ clinical expertise through peer-to-peer learning and collaborative partnerships with medical associations and the Orthopedic Learning Center.
We’re committed to developing the most advanced proprietary products as well as bringing the most innovative surgical devices into the CONMED portfolio. Our goal is always to provide you with a comprehensive suite of clinically superior products to help you improve patient outcomes, every day.
We’ve been focused on advancing surgery and patient care since day one.
Eugene looks to fill a need in the market by forming Enterprises and acquiring Mohawk Hospital Supply in Utica, NY.
Our founder, Eugene , developed an innovative disposable ECG electrode at his kitchen table and launched CONMED.
In our first acquisition as CONMED, we incorporated cutting-edge electrosurgical company Aspen Labs, a division of Bristol Myers Squibb, into our company.
CONMED more than doubles in size with the acquisition of Linvatec, which includes Hall surgical products. This forward-looking diversification helps grow our international footprint.
By acquiring the majority of the gastroenterology and pulmonary business from C.R. Bard, we expand our presence in the general surgery market and emerge as one of the biggest players in the industry.
An agreement with Musculoskeletal Transplant Foundation, the world’s largest tissue bank, gives us exclusive rights to their game-changing sports medicine allograft tissue.
CONMED furthers our commitment to continuous innovation with the acquisition of and, with it, , the first insufflation device with built-in smoke evacuation.
With the acquisition of Buffalo Filter, a leading surgical smoke evacuation and filter technology company, we cement our spot as the most cutting-edge surgical and patient care product company.
The acquisition of In2Bones Global, Inc. enhances CONMED’s solutions for the treatment of disorders and injuries in upper and lower extremities. The acquisition of Biorez, Inc. advances CONMED’s solution for soft tissue healing through BioBrace® implant technology.
The addition of Biorez and its proprietary BioBrace® Implant technology represents an important step forward for CONMED in advancing the next generation of soft tissue healing in sports medicine.
We believe it’s our capacity to innovate that sets us apart. We iterate on our products to ensure clinical excellence and embrace a mindset of constant improvement. As a result, we’ve come to own numerous areas of innovation.